I believe that to be so. That said I don't think the company would sit on top of good news for an extended period of time as it would invite insider trading. It could however possibly help line up how the results would be presented. If we were talking about a pivotal AD trial, then that might be a different situation but a 100 patient 2B trial would not necessarily be material if positive but certainly material if failure. That's my take after reading about this for the last several months on a competitor's MB.
Market Data 
Markets 
AI
